Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer

[1]  F. Couch,et al.  Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.

[2]  Xin Wang,et al.  Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation* , 2013, The Journal of Biological Chemistry.

[3]  三本 麗.  DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading snail , 2013 .

[4]  M. Schmitz,et al.  Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways. , 2012, Journal of molecular cell biology.

[5]  Y. Miki,et al.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. , 2012, The Journal of clinical investigation.

[6]  Soonmyung Paik,et al.  Gene-expression-based prognostic assays for breast cancer , 2010, Nature Reviews Clinical Oncology.

[7]  K. Kawahara,et al.  Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. , 2009, The Journal of thoracic and cardiovascular surgery.

[8]  S. Takeno,et al.  DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. , 2009, Anticancer research.

[9]  K. Yoshida.  Role for DYRK family kinases on regulation of apoptosis. , 2008, Biochemical pharmacology.

[10]  M. Oren,et al.  Mdm2: p53's lifesaver? , 2007, Molecular cell.

[11]  Y. Miki,et al.  DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. , 2007, Molecular cell.

[12]  H. Joost,et al.  Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.

[13]  M. Osborn,et al.  Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.